FDA OKs Phase 3 Trial of Masitinib for Progressive Forms of MS
The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3 clinical trial of its investigational treatment masitinibĀ in people with progressive forms of multiple sclerosis (MS). The decision follows approvals in several European countries that will also host trial sites, including…